Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma

L. Brambilla, R. Labianca, S. Fossati, V. Boneschi, S. Ferrucci, M. Clerici, G. Dallavalle

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A phase II evaluation of Vinorelbine is of interest in mediterranean Kaposi's sarcoma (MKS) because of the well-known activity of the natural Vinca alkaloids in this disease. Fifteen patients, both chemonaive and pretreated, were treated with Vinorelbina at the close level of 17.5 mg/sqm every 2 weeks, 5 times, then 30 mg/sqm every 3 weeks until maximal response (complete regression, or partial regression), followed by 3 consolidation courses. A partial regression was obtained in 9/15 (60%) patients, with higher activity in previously untreated patients as compared to pretreated patients. The duration of remission was 6 months in the first group and 2 months in the second one. The median survival (all patients) was 13+ months. Vinorelbine is an active drug in MKS and needs more extensive, evaluation in large, cooperative clinical trials.

Original languageEnglish
Pages (from-to)467-469
Number of pages3
JournalEuropean Journal of Dermatology
Volume5
Issue number6
Publication statusPublished - 1995

Fingerprint

Kaposi's Sarcoma
Pharmaceutical Preparations
Vinca Alkaloids
vinorelbine
Clinical Trials
Survival

Keywords

  • Chemotherapy
  • Mediterranean Kaposi's sarcoma
  • Vinorelbine

ASJC Scopus subject areas

  • Dermatology

Cite this

Brambilla, L., Labianca, R., Fossati, S., Boneschi, V., Ferrucci, S., Clerici, M., & Dallavalle, G. (1995). Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma. European Journal of Dermatology, 5(6), 467-469.

Vinorelbine : An active drug in Mediterranean Kaposi's sarcoma. / Brambilla, L.; Labianca, R.; Fossati, S.; Boneschi, V.; Ferrucci, S.; Clerici, M.; Dallavalle, G.

In: European Journal of Dermatology, Vol. 5, No. 6, 1995, p. 467-469.

Research output: Contribution to journalArticle

Brambilla, L, Labianca, R, Fossati, S, Boneschi, V, Ferrucci, S, Clerici, M & Dallavalle, G 1995, 'Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma', European Journal of Dermatology, vol. 5, no. 6, pp. 467-469.
Brambilla, L. ; Labianca, R. ; Fossati, S. ; Boneschi, V. ; Ferrucci, S. ; Clerici, M. ; Dallavalle, G. / Vinorelbine : An active drug in Mediterranean Kaposi's sarcoma. In: European Journal of Dermatology. 1995 ; Vol. 5, No. 6. pp. 467-469.
@article{aac82d11cd5848c7bc65b67d66e53705,
title = "Vinorelbine: An active drug in Mediterranean Kaposi's sarcoma",
abstract = "A phase II evaluation of Vinorelbine is of interest in mediterranean Kaposi's sarcoma (MKS) because of the well-known activity of the natural Vinca alkaloids in this disease. Fifteen patients, both chemonaive and pretreated, were treated with Vinorelbina at the close level of 17.5 mg/sqm every 2 weeks, 5 times, then 30 mg/sqm every 3 weeks until maximal response (complete regression, or partial regression), followed by 3 consolidation courses. A partial regression was obtained in 9/15 (60{\%}) patients, with higher activity in previously untreated patients as compared to pretreated patients. The duration of remission was 6 months in the first group and 2 months in the second one. The median survival (all patients) was 13+ months. Vinorelbine is an active drug in MKS and needs more extensive, evaluation in large, cooperative clinical trials.",
keywords = "Chemotherapy, Mediterranean Kaposi's sarcoma, Vinorelbine",
author = "L. Brambilla and R. Labianca and S. Fossati and V. Boneschi and S. Ferrucci and M. Clerici and G. Dallavalle",
year = "1995",
language = "English",
volume = "5",
pages = "467--469",
journal = "European Journal of Dermatology",
issn = "1167-1122",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Vinorelbine

T2 - An active drug in Mediterranean Kaposi's sarcoma

AU - Brambilla, L.

AU - Labianca, R.

AU - Fossati, S.

AU - Boneschi, V.

AU - Ferrucci, S.

AU - Clerici, M.

AU - Dallavalle, G.

PY - 1995

Y1 - 1995

N2 - A phase II evaluation of Vinorelbine is of interest in mediterranean Kaposi's sarcoma (MKS) because of the well-known activity of the natural Vinca alkaloids in this disease. Fifteen patients, both chemonaive and pretreated, were treated with Vinorelbina at the close level of 17.5 mg/sqm every 2 weeks, 5 times, then 30 mg/sqm every 3 weeks until maximal response (complete regression, or partial regression), followed by 3 consolidation courses. A partial regression was obtained in 9/15 (60%) patients, with higher activity in previously untreated patients as compared to pretreated patients. The duration of remission was 6 months in the first group and 2 months in the second one. The median survival (all patients) was 13+ months. Vinorelbine is an active drug in MKS and needs more extensive, evaluation in large, cooperative clinical trials.

AB - A phase II evaluation of Vinorelbine is of interest in mediterranean Kaposi's sarcoma (MKS) because of the well-known activity of the natural Vinca alkaloids in this disease. Fifteen patients, both chemonaive and pretreated, were treated with Vinorelbina at the close level of 17.5 mg/sqm every 2 weeks, 5 times, then 30 mg/sqm every 3 weeks until maximal response (complete regression, or partial regression), followed by 3 consolidation courses. A partial regression was obtained in 9/15 (60%) patients, with higher activity in previously untreated patients as compared to pretreated patients. The duration of remission was 6 months in the first group and 2 months in the second one. The median survival (all patients) was 13+ months. Vinorelbine is an active drug in MKS and needs more extensive, evaluation in large, cooperative clinical trials.

KW - Chemotherapy

KW - Mediterranean Kaposi's sarcoma

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0028844447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028844447&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028844447

VL - 5

SP - 467

EP - 469

JO - European Journal of Dermatology

JF - European Journal of Dermatology

SN - 1167-1122

IS - 6

ER -